Sign up
Pharma Capital
EPIC: TRX
Market: AIM
52-week High/Low: 12.00p / 5.40p
Sector: Pharma & Biotech
Market Cap: 69.13M

Tissue Regenix Group plc is a pioneering, international medical technology company, leading the development of regenerative products to make replacement body parts using biological (human & animal) tissues.

Tissue Regenix Group PLC

www.tissueregenix.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Tissue Regenix Group PLC

Tissue Regenix Group PLC Snapshot

Improve quality of life for patient's

Tissue Regenix is developing and commercializing a range of medical devices and treatments based on our patented dCELL® process. We have established operations in the US and UK to target multi-billion dollar global healthcare markets.
Tissue Regenix is currently focusing on three core treatment areas, through its TRX Wound Care, TRX Cardiac and TRX Orthopaedics divisions, working with our research partners, including the University of Leeds, Brazil’s Pontifical University of Parana, and NHSBT, to commercialise the intellectual property rights they generate.

The Board

John Samuel
Chairman

Steve Couldwell
Chief Executive Officer

Gareth Jones
Chief Financial Officer

Alan Miller
Non Executive-Director

Randeep Singh Grewal
Non Executive-Director

Jonathan Glenn
Non-Executive Director

Shervanthi Homer-Vanniasinkam
Non-Exectuive Director


 

Significant shareholders

As at 19 February 2019, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:

Name of Shareholder % of Voting Rights
Invesco Limited 28.74
Woodford Investment Management LLP 26.00
Techtran Group Limited 8.79
Baillie Gifford & Co Ltd 6.04
Jupiter Asset Management 5.88
Directors & Related Holdings 4.28
IP2IPO Limited 4.27

Shares not in public hands as at 19 February 2019 – 856,002,530 - 73%

Shares in issue as at 19 February 2019 - 1,171,730,823 ordinary shares of 0.5p each

The securities of Tissue Regenix Group plc are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

Tissue Regenix Ltd

Unit 1&2
Astley Way
Astley Lane Industrial Estate
Swillington
Leeds, LS26 8XT
United Kingdom

Tel:
0330 430 3052

Fax:
+44 (0)1904 380517

Email:
[email protected]

Investor or Media enquiries

Caitlin Pearson

Corporate Communications Director

[email protected]

 

Nominated Advisor and Broker

Jefferies International,
68 Upper Thames Street,
London,
EC4V 3BJ

Auditors

KPMG Audit Plc,
1 The Embankment,
Neville Street,
Leeds LS1 4DW

Solicitors

DLA Piper UK LLP,
Princes Exchange,
Princes Square,
Leeds LS1 4BY

Registrars

Capita Registrars Ltd,
34 Beckenham Rd,
Beckenham,
Kent BR3 4TU

 

View full TRX profile View Profile
View All

Market Reports Including TRX

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.